PROADM AS MARKER INDICATING AN ADVERSE EVENT Application EP-4220175-A1 European Patent Office 02 Aug 2023
Diagnosis and risk stratification of fungal infections Grant US-11592450-B2 United States of America 28 Feb 2023
PRO-ADM FOR THERAPY MONITORING OF INTENSIVE CARE UNIT PATIENTS Application EP-4027145-A1 European Patent Office 13 Jul 2022
Proadrenomedullin as a marker for abnormal platelet levels Grant US-11327082-B2 United States of America 10 May 2022
PROADRENOMEDULLIN AS A MARKER FOR ABNORMAL PLATELET LEVELS Application EP-3971573-A1 European Patent Office 23 Mar 2022
PROADRENOMEDULLIN AS A MARKER FOR ABNORMAL PLATELET LEVELS Application EP-3971572-A1 European Patent Office 23 Mar 2022
PRO-ADRENOMEDULLIN FOR PROGNOSING DISEASE PROGRESSION IN SEVERE ACUTE RESPIRATORY… Application WO-2021204770-A1 World Intellectual Property Organisation (WIPO) 14 Oct 2021
PROADRENOMEDULLIN AS A MARKER FOR ABNORMAL PLATELET LEVELS Application WO-2019053118-A1 World Intellectual Property Organisation (WIPO) 21 Mar 2019
METHOD FOR GUIDANCE OF FLUID THERAPY BASED ON PROADRENOMEDULLIN Application WO-2019053116-A1 World Intellectual Property Organisation (WIPO) 21 Mar 2019
PCT AND PRO-ADM AS MARKERS FOR MONITORING ANTIBIOTIC TREATMENT Application WO-2019053117-A1 World Intellectual Property Organisation (WIPO) 21 Mar 2019
PRO-ADM AS A THERAPY MONITORING MARKER FOR CRITCALLY ILL PATIENTS Application WO-2019053115-A1 World Intellectual Property Organisation (WIPO) 21 Mar 2019
PROADM AS MARKER INDICATING AN ADVERSE EVENT Application WO-2018141840-A1 World Intellectual Property Organisation (WIPO) 09 Aug 2018